Skip to main content

Bakkt, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

BKKT$4.17-10.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

(in thousands)

Six Months EndedJune 30, 2026Six Months EndedJune 30, 2025
Cash flows from operating activities:
Net (loss) income$69,191$(13,915)
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization1,118374
Non-cash lease expense—566
Share-based compensation expense4,6979,681
Impairment of long-lived assets1,246—
Loss on sale of Bakkt Trust—2,301
Gain on lease assignment—(1,755)
Gain from change in fair value of warrant liability(6,116)(23,644)
Loss on equity method investment504—
Change in fair value of Transchem warrant and derivative asset(97,820)—
Professional fees paid in stock1,125—
Other5887
Changes in operating assets and liabilities:
Accounts receivable(349)1,672
Prepaid insurance1,8241,904
Deposits with clearing house——
Accounts payable and accrued liabilities(5,029)3,592
Unsettled crypto trades(1,304)—
Due to related party—(2,360)
Deferred revenue(745)(535)
Operating lease liabilities(573)(2,698)
Customer funds payable5,920(67,230)
Assets and liabilities of businesses held for sale—(3,476)
Other assets and liabilities(657)(493)
Net cash used in operating activities(26,910)(95,929)
Cash flows from investing activities:
Capitalized internal-use software development costs and other capital expenditures(1,987)(149)
Proceeds from Sale of Bakkt Trust—4,518
Cash received from settlement of derivative arrangement2,677—
Purchase of investments(14)—
Consideration for the acquisition of DTR(3,200)—
Consideration for the acquisition of Gyzer(253)—
Investment in Swan(250)—
Investment in Transchem warrant(9,410)—
Net cash (used in) provided by investing activities(12,437)4,369
Cash flows from financing activities:
Proceeds from the exercise of warrants—1
Withholding tax payments on net share settlements on equity awards(329)(1,712)
Proceeds from Equity offerings69,602—
Cash paid for Equity offerings(2,541)—
Exercise of stock options500—
Proceeds from borrowings on revolving credit facility—5,000
Repayments on revolving credit facility—(5,000)
Cash paid for financing costs—(775)
Proceeds from issuance of convertible debentures, net of issuance costs—23,750
Net cash provided by financing activities67,23221,264
Effect of exchange rate changes54915
Net increase (decrease) in cash, cash equivalents, restricted cash, customer funds and deposits27,939(69,381)
Cash, cash equivalents, restricted cash, customer funds and deposits at the beginning of the period44,902153,746
Cash, cash equivalents, restricted cash, customer funds and deposits at the end of the period$72,841$84,365
Supplemental disclosure of cash flow information:
Non-cash operating lease right-of-use asset acquired$82$—
Supplemental disclosure of non-cash investing and financing activity:
Non-cash acquisition consideration103,661—
Reconciliation of cash, cash equivalents, restricted cash, customer funds and deposits to consolidated balance sheets:
Cash and cash equivalents$49,980$43,493
Restricted cash71817,965
Customer funds20,58221,336
Deposits (Note 7)1,5611,571
Total cash, cash equivalents, restricted cash, customer funds and deposits$72,841$84,365
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.